BioLine RX (Israel) Investor Sentiment

BLRX Stock  ILS 2.40  0.80  25.00%   
About 62% of BioLine RX's investor base is looking to short. The analysis of current outlook of investing in BioLine RX suggests that many traders are alarmed regarding BioLine RX's prospects. The current market sentiment, together with BioLine RX's historical and current headlines, can help investors time the market. In addition, many technical investors use BioLine RX stock news signals to limit their universe of possible portfolio assets.
  
over a week ago at news.google.com         
BioLineRx announces change to ratio of ADS to ordinary shares - MSN
Google News at Macroaxis
over two weeks ago at news.google.com         
BioLineRx stock touches 52-week low at 0.14 amid downturn - Investing.com
Google News at Macroaxis
over three weeks ago at news.google.com         
BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks
Google News at Macroaxis
over three weeks ago at news.google.com         
BioLineRx Announces 10 Million Direct Offering to Fuel Growth - TipRanks
Google News at Macroaxis
over a month ago at news.google.com         
BLRX Stock Earnings BioLine Rx Beats EPS for Q1 2024 - MSN
Google News at Macroaxis
over two months ago at news.google.com         
BLRX - BioLineRX Ltd Latest Stock News Market Updates - StockTitan
Google News at Macroaxis
over two months ago at news.google.com         
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Driv...
Google News at Macroaxis
over two months ago at news.google.com         
BioLineRx stock sinks on share purchase deal - Seeking Alpha
Google News at Macroaxis
over two months ago at news.google.com         
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Morningstar
Google News at Macroaxis
over two months ago at news.google.com         
BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
BioLineRx stock hits 52-week low at 0.5 amid market challenges - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
BioLineRx shares initiated with Buy rating, 2 target - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
BioLineRx Schedules Annual Shareholders Meeting - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Earnings call BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about BioLine RX that are available to investors today. That information is available publicly through BioLine media outlets and privately through word of mouth or via BioLine internal channels. However, regardless of the origin, that massive amount of BioLine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioLine RX news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioLine RX relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioLine RX's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioLine RX alpha.

BioLine RX Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for BioLine Stock analysis

When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities